Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a trials. The company also develops PLN-1474,...
Company Valuation
From both historical and forecast perspectives, the stock is fairly priced compared to similar stocks.
Target Price
The average target price of PLRX is 3.5 and suggests 201% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increa
Buy
Sell